EUVIMEDEUVIMED entdecken
Crossref

A New Class of Multitargeting Pt IV Anticancer Agents: Prodrugs That Release Pt II Drugs and Bioactive Moieties Tethered to Pt IV via a Tertiary Amine

Moumita Maji iD, Michele De Franco, Sourav Acharya iD, Dan Gibson iD, Valentina Gandin iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.5c02501 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Moumita Maji und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel. Hauptthemen laut MEDLINE: Antineoplastic Agents, Prodrugs, Amines, Protein Kinase Inhibitors. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Israel Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In most multi-action PtIV prodrugs previously reported, the bioactive molecules have carboxylate, hydroxyl, primary, or secondary amine groups through which they are tethered to the axial position of the PtIV directly or via self-immolative linkers. A major challenge is to expand the range to bioactive molecules that can be released in their active form from PtIV prodrugs to molecules having a tertiary amine. Herein, we describe the general approach for design and synthesis of PtIV complexes conjugated to organic drugs (brigatinib, osimertinib, adavosertib, and irinotecan) via their tertiary amines. The complexes are stable and release the active drugs upon reduction. The PtIV prodrugs conjugated to tyrosine kinase inhibitors (TKIs) showed potent anticancer activity in 2D and 3D cancer models by combining the modes of action of platinum and TKi. They inhibited in vivo tumor growth in an LLC model better than brigatinib, osimertinib, and cisplatin with significantly lower body weight loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsProdrugsAminesProtein Kinase InhibitorsOrganoplatinum CompoundsHumansAnimalsCell Line, TumorMicePyrimidinesAniline CompoundsIndoles

Substanzen

Antineoplastic AgentsProdrugsAminesProtein Kinase InhibitorsOrganoplatinum CompoundsPyrimidinesAniline CompoundsIndoles

Autor:innen und Institutionen

  • Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
  • Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, Padova 35131, Italy.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, United States.

ORCID-Profile: Moumita Maji, Sourav Acharya, Dan Gibson, Valentina Gandin

Förderung

  • Israel Science Foundation

Zitieren

APA

Maji, M., De Franco, M., Acharya, S., Gibson, D., & Gandin, V. (2026). A New Class of Multitargeting Pt IV Anticancer Agents: Prodrugs That Release Pt II Drugs and Bioactive Moieties Tethered to Pt IV via a Tertiary Amine. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02501

Vancouver

Maji M, De Franco M, Acharya S, Gibson D, Gandin V. A New Class of Multitargeting Pt IV Anticancer Agents: Prodrugs That Release Pt II Drugs and Bioactive Moieties Tethered to Pt IV via a Tertiary Amine. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c02501

BibTeX
@article{Maji2026,
  author = {Maji, Moumita and De Franco, Michele and Acharya, Sourav and Gibson, Dan and Gandin, Valentina},
  title = {A New Class of Multitargeting Pt IV Anticancer Agents: Prodrugs That Release Pt II Drugs and Bioactive Moieties Tethered to Pt IV via a Tertiary Amine},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.5c02501}
}
Kostenlos starten →